Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Idexx Laboratories, Inc shares valued at $651,621 were purchased by SZOSTAK M ANNE on May 21 ’25. At $517.16 per share, SZOSTAK M ANNE acquired 1,260 shares.
Also, JUNIUS DANIEL M sold 2,683 shares, netting a total of over 1,358,697 in proceeds. Following the sale of shares at $506.41 each, the insider now holds 3,304 shares.
Before that, JUNIUS DANIEL M had added 2,683 shares to its account. In a trade valued at $1,358,697, the Director bought Idexx Laboratories, Inc shares for $506.41 each.
As published in their initiating research note from Leerink Partners on December 02, 2024, Idexx Laboratories, Inc [IDXX] has been an Outperform and the price target has been revised to $500. Analysts at BTIG Research started covering the stock with ‘”a Buy”‘ outlook in a report released in late July. As of January 30, 2024, Piper Sandler has decreased its “an Overweight” rating to a “Neutral” for IDXX. Earlier on December 07, 2023, Exane BNP Paribas initiated its rating. Their recommendation was “an Outperform” for IDXX stock.
Analyzing IDXX Stock Performance
During the last five days, there has been a drop of approximately -1.40%. Over the course of the year, Idexx Laboratories, Inc shares have jumped approximately 22.10%. Shares of the company reached a 52-week high of $523.48 on 05/20/25 and a 52-week low of $356.14 on 04/09/25.
Support And Resistance Levels for Idexx Laboratories, Inc (IDXX)
According to the 24-hour chart, there is a support level at 498.56, which, if violated, would cause prices to drop to 492.29. In the upper region, resistance lies at 509.56. The next price resistance is at 514.28. RSI (Relative Strength Index) is 65.27 on the 14-day chart, showing neutral technical sentiment.
